Treatment of advanced, progressive epidemic Kaposi's sarcoma (EKS): a phase-II study.
The design of a prospective phase-II study on the treatment of Kaposi's sarcoma (KS) in patients with HIV infection is described. In this study the toxicity and antineoplastic activity of high-dose alpha-interferon (20 x 10(6) U/m2 s.c. daily) will be investigated in patients with advanced and progressive KS. Patients with progressing KS during IFN treatment or with relapsing KS after IFN will be treated with vinblastine (4 mg/m2 i.v., days 1, 8, and 15) and bleomycin (15 mg i.v., days 1 + 8). The study was only recently activated; results are so far not available.
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000628:therapy*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage
D007370:Interferon Type I; D011994:Recombinant Proteins; D001761:Bleomycin; D014747:Vinblastine